JP5452231B2 - 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン - Google Patents
化学的に修飾した正常な細胞由来の抗腫瘍ワクチン Download PDFInfo
- Publication number
- JP5452231B2 JP5452231B2 JP2009544412A JP2009544412A JP5452231B2 JP 5452231 B2 JP5452231 B2 JP 5452231B2 JP 2009544412 A JP2009544412 A JP 2009544412A JP 2009544412 A JP2009544412 A JP 2009544412A JP 5452231 B2 JP5452231 B2 JP 5452231B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- lymphocytes
- antigen
- composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 16
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 6
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 162
- 210000004027 cell Anatomy 0.000 claims abstract description 149
- 108091007433 antigens Proteins 0.000 claims abstract description 94
- 102000036639 antigens Human genes 0.000 claims abstract description 94
- 239000000427 antigen Substances 0.000 claims abstract description 93
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 85
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 48
- 230000014509 gene expression Effects 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 230000035755 proliferation Effects 0.000 claims abstract description 30
- 210000001550 testis Anatomy 0.000 claims abstract description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 19
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 15
- 238000009169 immunotherapy Methods 0.000 claims abstract description 13
- 230000002062 proliferating effect Effects 0.000 claims abstract description 13
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims abstract description 9
- 230000004913 activation Effects 0.000 claims abstract description 8
- 230000035131 DNA demethylation Effects 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- 230000001472 cytotoxic effect Effects 0.000 claims description 30
- 231100000433 cytotoxic Toxicity 0.000 claims description 26
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000003698 anagen phase Effects 0.000 claims description 7
- 230000006195 histone acetylation Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000006197 histone deacetylation Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 11
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000006698 induction Effects 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 15
- 102000000588 Interleukin-2 Human genes 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 12
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 12
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 11
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 11
- 230000001464 adherent effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000012737 microarray-based gene expression Methods 0.000 description 10
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 108010047620 Phytohemagglutinins Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001885 phytohemagglutinin Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 5
- 102100033467 L-selectin Human genes 0.000 description 5
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 3
- 230000000961 alloantigen Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000012595 freezing medium Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000012649 demethylating agent Substances 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001159 endocytotic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 231100000405 induce cancer Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229930185603 trichostatin Natural products 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000012650 DNA demethylating agent Substances 0.000 description 1
- 229940045805 DNA demethylating agent Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010968 computed tomography angiography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057056 human CTCFL Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940075628 hypomethylating agent Drugs 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| GB0700058.1 | 2007-01-03 | ||
| PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514455A JP2010514455A (ja) | 2010-05-06 |
| JP2010514455A5 JP2010514455A5 (https=) | 2012-10-25 |
| JP5452231B2 true JP5452231B2 (ja) | 2014-03-26 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544412A Expired - Fee Related JP5452231B2 (ja) | 2007-01-03 | 2008-01-03 | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (https=) |
| EP (1) | EP2102331B1 (https=) |
| JP (1) | JP5452231B2 (https=) |
| AT (1) | ATE522600T1 (https=) |
| AU (1) | AU2008203730B2 (https=) |
| CY (1) | CY1112668T1 (https=) |
| DK (1) | DK2102331T3 (https=) |
| ES (1) | ES2372713T3 (https=) |
| GB (1) | GB0700058D0 (https=) |
| HR (1) | HRP20110899T1 (https=) |
| PL (1) | PL2102331T3 (https=) |
| PT (1) | PT2102331E (https=) |
| SI (1) | SI2102331T1 (https=) |
| WO (1) | WO2008081035A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801751A1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8467973B2 (en) * | 2009-07-28 | 2013-06-18 | Promising Future, Llc | Pairing processes for preparing alloreactive cytotoxic T cells |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| JP5816627B2 (ja) * | 2009-10-27 | 2015-11-18 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| MX388325B (es) | 2015-05-28 | 2025-03-19 | Kite Pharma Inc | Metodos de diagnostico para tratamiento con linfocitos t. |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| EP3364969A4 (en) | 2015-10-20 | 2019-07-10 | Kite Pharma, Inc. | METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY |
| CN109414455B (zh) | 2016-04-01 | 2023-01-20 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| KR20200068750A (ko) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| PT3436079T (pt) | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
| PT3583129T (pt) | 2017-02-14 | 2021-12-14 | Kite Pharma Inc | Moléculas de ligação a cd70 e seus métodos de uso |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| EP3490605B1 (en) | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| AU2018250148B2 (en) | 2017-04-03 | 2021-09-23 | Kite Pharma, Inc. | Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells |
| SG10201912400VA (en) | 2017-04-24 | 2020-02-27 | Kite Pharma Inc | Humanized antigen-binding domains against cd19 and methods of use |
| TWI862477B (zh) | 2017-05-26 | 2024-11-21 | 美商凱特製藥公司 | 製備和使用胚胎間充質先驅細胞的方法 |
| KR20230052312A (ko) | 2017-09-15 | 2023-04-19 | 카이트 파마 인코포레이티드 | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 |
| CA3076099A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Linkers for chimeric antigen receptors |
| CA3084470A1 (en) | 2017-10-18 | 2019-04-25 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| BR112020014446A2 (pt) | 2018-01-15 | 2020-12-29 | Pfizer Inc. | Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb |
| WO2019152957A1 (en) | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| CN112534044A (zh) | 2018-02-16 | 2021-03-19 | 凯德药业股份有限公司 | 经修饰的多能干细胞及制备和使用方法 |
| TWI784324B (zh) | 2018-04-12 | 2022-11-21 | 美商凱特製藥公司 | 利用腫瘤微環境之特性之嵌合受體t細胞治療 |
| KR102544086B1 (ko) | 2018-06-01 | 2023-06-16 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| US20210155941A1 (en) | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| SG11202101014XA (en) | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| KR102840400B1 (ko) | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| US20220175900A1 (en) * | 2019-04-12 | 2022-06-09 | Cytovac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| US20200384027A1 (en) | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| KR20220054383A (ko) | 2019-09-03 | 2022-05-02 | 알로젠 테라퓨틱스 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| IL292665B2 (en) | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| US12152251B2 (en) | 2020-08-25 | 2024-11-26 | Kite Pharma, Inc. | T cells with improved functionality |
| US20220155299A1 (en) | 2020-10-28 | 2022-05-19 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| AU2021410635A1 (en) | 2020-12-24 | 2023-06-29 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
| WO2022150582A1 (en) | 2021-01-10 | 2022-07-14 | Kite Pharma, Inc. | T cell therapy |
| EP4281545A1 (en) | 2021-01-21 | 2023-11-29 | CytoVac A/S | Method for t-cell expansion and related medical applications |
| TW202241469A (zh) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| IL305571A (en) | 2021-03-11 | 2023-10-01 | Kite Pharma Inc | Improving the function of immune system cells |
| AU2022259428A1 (en) | 2021-04-16 | 2023-10-26 | Kite Pharma, Inc. | Taci/bcma dual binding molecules |
| WO2022221126A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| EP4337227A2 (en) | 2021-05-14 | 2024-03-20 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| IL308696A (en) | 2021-05-24 | 2024-01-01 | Kite Pharma Inc | Nkg2d-based chimeric antgen receptor |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| JP2024525485A (ja) | 2021-07-02 | 2024-07-12 | カイト ファーマ インコーポレイテッド | 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法 |
| WO2023009989A1 (en) | 2021-07-26 | 2023-02-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| US20230268031A1 (en) | 2021-07-30 | 2023-08-24 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
| TWI863006B (zh) | 2021-10-18 | 2024-11-21 | 美商凱特製藥公司 | 用於嵌合抗原受體之信號傳導域 |
| US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| KR20250097844A (ko) | 2022-10-28 | 2025-06-30 | 카이트 파마 인코포레이티드 | 면역요법의 효능 향상 및 지속적인 반응 |
| WO2024092227A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
| KR20250162836A (ko) | 2023-03-17 | 2025-11-19 | 카이트 파마 인코포레이티드 | 종양 미세환경이 면역요법의 효능에 미치는 영향 |
| WO2025096517A1 (en) | 2023-11-01 | 2025-05-08 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| US20250262300A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| WO2025188561A1 (en) | 2024-03-04 | 2025-09-12 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| WO2025231376A1 (en) | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Chimeric receptors binding to cll-1 and methods of use thereof |
| WO2025250819A1 (en) | 2024-05-31 | 2025-12-04 | Kite Pharma, Inc. | Tricistronic constructs for anti-gpc3 car |
| US20260009001A1 (en) | 2024-07-08 | 2026-01-08 | Kite Pharma, Inc. | Systems and methods for applying mechanical force to living cells to generate a phenotypic response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en not_active Ceased
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10023839B2 (en) | 2018-07-17 |
| PT2102331E (pt) | 2011-12-19 |
| WO2008081035A1 (en) | 2008-07-10 |
| HRP20110899T1 (hr) | 2011-12-31 |
| US20180036397A1 (en) | 2018-02-08 |
| CY1112668T1 (el) | 2016-02-10 |
| PL2102331T3 (pl) | 2012-01-31 |
| AU2008203730B2 (en) | 2013-11-07 |
| EP2102331A1 (en) | 2009-09-23 |
| DK2102331T3 (da) | 2011-10-17 |
| AU2008203730A1 (en) | 2008-07-10 |
| JP2010514455A (ja) | 2010-05-06 |
| SI2102331T1 (sl) | 2012-01-31 |
| EP2102331B1 (en) | 2011-08-31 |
| ATE522600T1 (de) | 2011-09-15 |
| GB0700058D0 (en) | 2007-02-07 |
| ES2372713T3 (es) | 2012-01-25 |
| US20100092498A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5452231B2 (ja) | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン | |
| Grauer et al. | Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma model | |
| CN100591762C (zh) | 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途 | |
| EP1448229B1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| US11684671B2 (en) | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination | |
| EP3255143A2 (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| EP2603582B1 (en) | Compositions and methods for producing dendritic cells | |
| Whiteside | Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor | |
| EP2302038A1 (en) | Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses | |
| Sprinzl et al. | Dendritic cell vaccines for cancer therapy | |
| Piemonti et al. | Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability | |
| Vichchatorn et al. | Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme | |
| Hatakeyama et al. | Induction of autologous CD4-and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell–loaded dendritic cells | |
| JP7390740B2 (ja) | 腫瘍の治療及び／又は予防のための組成物 | |
| Abe et al. | Targeted cancer therapy by dendritic cell vaccine | |
| Yuan et al. | The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases | |
| Schöttker et al. | Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells | |
| HK1068913B (en) | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120904 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131029 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5452231 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |